Rocket Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Rocket Pharmaceuticals

26/02/2024 21:51

* Rocket Pharmaceuticals Inc  RCKT.OQ  reported a quarterly
adjusted loss of 64 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -92 cents.  The mean expectation of
thirteen analysts for the quarter was for a loss of 79 cents per
share. Wall Street expected results to range from -89 cents
to -67 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Rocket Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 64 cents​.
    * The company reported a quarterly loss of $59.66 million.
    * Rocket Pharmaceuticals Inc shares had fallen by 2.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Rocket
Pharmaceuticals Inc is $49.50 
This summary was machine generated from LSEG data February 26 at
09:50 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.79          -0.64          Beat
 Sep. 30 2023      -0.81          -0.75          Beat
 Jun. 30 2023      -0.79          -0.82          Missed
 Mar. 31 2023      -0.85          -0.73          Beat